相关实验视频

Updated: Jun 27, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

结合转录和表转录的分析确定THBS1是前列腺癌中恩扎拉胺耐药性的调节剂

Emmanuelle Hodara¹, Lisa Swartz¹, Aubree Mades¹

¹Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC and Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

Cancer heterogeneity and plasticity

|April 30, 2025

概括

N6-甲基氨酸 (m⁶A) RNA的修改影响了癌症药物耐药性. 在前列腺癌中,m⁶A的变化和THBS1表达的降低驱动了快速的酶胺耐药性.

科学领域:

分子生物学分子生物学
癌症研究癌症研究
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

癌症药物耐药性涉及适应性转录程序.
N6-甲基氨酸 (m6A) RNA修饰调节mRNA处理并影响细胞命运.
前列腺癌 (PC) 对恩扎胺 (ARPI) 的耐药性与雄激素受体 (AR) 的改变有关.

研究的目的:

调查m6A修改在PC中过渡到酶胺耐药性的作用.
为了识别受抗性发展过程中m⁶A修改影响的特定转录.

主要方法:

利用甲基-RNA-免疫沉,然后进行测序 (MeRIP-seq) 和RNA-seq.
比较了对恩扎胺胺敏感和耐药PC细胞之间的m6A概况和基因表达.
使用生物信息学工具 (GO,GSEA,TCGA,ORIEN) 优先选择候选基因.

主要成果:

鉴定了487个差异甲基化和表达的转录.
验证了六个顶级候选者,包括THBS1,在耐药细胞中显示了增加的m6A和降低的转录水平.
在敏感细胞中THBS1的siRNA-knockdown诱导了酶胺耐药性.

结论:

m⁶A 修改在PC中对酶氨胺耐药性的发展中发挥着重要作用.
降低THBS1的调节直接导致了快速的酶胺耐药性.
THBS1是前列腺癌急性耐药性的潜在驱动因素,代表了一个新的治疗标.

关键词:

这就是 MeRIP-seq4q4 的原因.在RNA甲基化过程中7 药物耐药性6 药物耐药性具有对酶胺的耐药性5 经过转录的表征性1 m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m6A2m 前列腺癌3是什么样的癌症

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...